London, England, United Kingdom The main department of described VC is located in the London. The company was established in Europe in United Kingdom.
Among the most successful fund investment fields, there are Medical, Health Diagnostics. The fund has exact preference in some founders of portfolio startups. For fund there is no match between the location of its establishment and the land of its numerous investments - Sweden. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight MerLion Pharma, Dilafor, EyeSense AG.
This Rosetta Capital works on 7 percentage points less the average amount of lead investments comparing to the other organizations. The top amount of exits for fund were in 2019. The real fund results show that this VC is 2 percentage points more often commits exit comparing to other companies. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2013. The usual things for fund are deals in the range of 10 - 50 millions dollars.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Rosetta Capital, startups are often financed by Novartis Venture Fund, Kurma Partners, BZ Bank. The meaningful sponsors for the fund in investment in the same round are Praktikerinvest, Ostersju00f6stiftelsen, btov Partners. In the next rounds fund is usually obtained by HealthCap, Versant Ventures, Sectoral Asset Management.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Carrick Therapeutics | $60M | 01 Dec 2022 | Dublin, County Dublin, Ireland | ||
NovImmune | $66M | 17 Feb 2014 | Geneva, Switzerland | ||
Aprea | 01 Jan 2013 | Stockholm, Stockholm County, Sweden | |||
| $7M | 11 Oct 2010 | Central | |||
EyeSense AG | $11M | 10 Feb 2006 | Germany, Bavaria, Germany |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Carrick Therapeutics | $60M | 01 Dec 2022 | Dublin, County Dublin, Ireland | ||
NovImmune | $66M | 17 Feb 2014 | Geneva, Switzerland | ||
Aprea | 01 Jan 2013 | Stockholm, Stockholm County, Sweden | |||
| $7M | 11 Oct 2010 | Central | |||
EyeSense AG | $11M | 10 Feb 2006 | Germany, Bavaria, Germany |
